Merck ends the sorry saga of BTK inhibitor it got from ArQule
Merck has ended development of a BTK inhibitor that was the main reason it bought ArQule for $2.7 billion in 2019. Nemtabrutinib, or MK-1026, was being investigated in a slew of trials in blood cancers ...
comments(0)
5-min edit window · permanent after that